SCHEMBL6412503

SCHEMBL6412503

COc1ccc(CN(Cc2ccc(F)cc2)C(=O)/C=C(\O)C(=O)O)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MITF O75030 1/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NR1H4 Q96RI1 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
LPAR1 Q92633 3/20 0.41
LPAR5 Q9H1C0 3/20 0.41
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PTPN1 P18031 1/20 0.39
CCR3 P51677 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6412506 1.00 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1KDM4EMITF
SCHEMBL6412983 0.81 TDP1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL6412980 0.81 TDP1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL6413735 0.80 BCL2A1 (0.53) ALDH1A1HTTRAB9APTPN1
SCHEMBL6413732 0.80 BCL2A1 (0.53) ALDH1A1HTTRAB9APTPN1
SCHEMBL6414516 0.80 KDM4E (0.51) ALDH1A1KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL6414519 0.80 KDM4E (0.51) ALDH1A1KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL6415776 0.79 ALDH1A1 (0.47) ALDH1A1L3MBTL1RAB9A
SCHEMBL6415771 0.79 ALDH1A1 (0.47) ALDH1A1L3MBTL1RAB9A
SCHEMBL6411753 0.78 TP53 (0.42) ALDH1A1KMT2AMEN1KDM4EMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
EP-1322599-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-02 EP disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed
WO-2001096283-A9 HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-10-17 WO disclosed
WO-2001096283-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 ALDH1A1 1020/4885KMT2A 1208/4885MEN1 4741/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 ALDH1A1 239/4885KMT2A 1330/4885MEN1 4837/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 ALDH1A1 239/4885KMT2A 1330/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.